紫杉醇联合唑来膦酸治疗恶性骨肿瘤的效果分析

Clinical Analysis of Paclitaxel Combined with Zolledronic Acid in Treatment of Malignant Bone Tumors

目的探讨紫杉醇联合唑来膦酸治疗恶性骨肿瘤的临床效果及对患者VAS评分的影响。方法选取我院收治的恶性骨肿瘤患者60例,随机分为两组,对照组使用紫杉醇治疗,研究组使用紫杉醇联合唑来膦酸治疗。对比两组患者的临床治疗效果、不良反应、镇痛效果以及不同时间点的VAS评分。结果研究组疗效显著优于对照组(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组镇痛效果显著优于对照组(P<0.05);研究组VAS评分显著优于对照组(P<0.05)。结论紫杉醇联合唑来膦酸治疗恶性骨肿瘤患者的临床治疗效果较理想。

Objective To explore the clinical effects of paclitaxel combined with zolledronic acid in the treatment of malignant bone tumor and its effects on VAS score of patients. Methods A total of 60 patients with malignant bone tumor treated in our hospital were ran- domly divided into two groups. The control group was treated with paelitaxel, and the study group was treated with paelitaxel and zoledronie acid. The clinical effects, adverse reactions, analgesic effects and VAS scores at different time points were compared between the two groups. Results After treatment, the curative effect of the study group was significantly better than that of the control group （P 〈 0.05）. The incidence of adverse reactions in the study group was significantly lower than in the control group （P 〈 0.05）. The analgesic effect of the study group was significantly better than that of the control group （P 〈 0.05）. The VAS score of the study group was also significantly better than that of the control group （P 〈 0.05）. Conclusion Paelitaxel combined with zolledronie acid had good curative effects in the treatment of patients with malignant bone tumor.